Sonoma Pharmaceuticals (SNOA) Accumulated Expenses (2011 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Accumulated Expenses of $1.7 million for Q1 2026, down 1.04% year-over-year from $1.7 million in Q1 2025, and down 1.04% quarter-over-quarter from $1.7 million in Q1 2025.
Sonoma Pharmaceuticals (SNOA) Accumulated Expenses (2011 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Accumulated Expenses history runs 14 years deep, the most recent figure standing at $1.7 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 1.04% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (down 1.04% YoY), while the FY2026 annual figure was $1.7 million, down 1.04% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $1.7 million, down from $1.7 million in the prior quarter.
- The five-year high for Accumulated Expenses was $1.7 million in Q1 2025, with the low at $1.1 million in Q1 2022.
- The 5-year median for Accumulated Expenses is $1.5 million (2023), against an average of $1.5 million.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses jumped 38.15% in 2023, then slipped 3.01% in 2024.
- Sonoma Pharmaceuticals' Accumulated Expenses stood at $1.1 million in 2022, then surged by 38.15% to $1.5 million in 2023, then retreated by 3.01% to $1.4 million in 2024, then increased by 22.41% to $1.7 million in 2025, then retreated by 1.04% to $1.7 million in 2026.
- Business Quant data shows SNOA's Accumulated Expenses at $1.7 million in Q1 2026, $1.7 million in Q1 2025, and $1.4 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.72 Mn |
| Mar 31, 2025 | 1.74 Mn |
| Mar 31, 2024 | 1.42 Mn |
| Mar 31, 2023 | 1.46 Mn |
| Mar 31, 2022 | 1.06 Mn |
| Mar 31, 2021 | 787,000.00 |
| Mar 31, 2020 | 1.08 Mn |
| Mar 31, 2019 | 957,000.00 |
| Sep 30, 2018 | 1.17 Mn |
| Jun 30, 2018 | 1.42 Mn |
| Mar 31, 2018 | 817,000.00 |
| Dec 31, 2017 | 1.17 Mn |
| Sep 30, 2017 | 1.17 Mn |
| Jun 30, 2017 | 1.17 Mn |
| Mar 31, 2017 | 681,000.00 |
| Dec 31, 2016 | 1.19 Mn |
| Sep 30, 2016 | 944,000.00 |
| Jun 30, 2016 | 944,000.00 |
| Mar 31, 2016 | 693,000.00 |
| Mar 31, 2015 | 545,000.00 |